DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,533,014 B2 Henn Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,533,014 B2 Henn Et Al USOO9533 014B2 (12) United States Patent (10) Patent No.: US 9,533,014 B2 Henn et al. (45) Date of Patent: *Jan. 3, 2017 (54) SYNERGISTIC BACTERIAL COMPOSITIONS (52) U.S. CI. AND METHODS OF PRODUCTION AND USE CPC .............. A61K 35/74 (2013.01); A23L 33/127 THEREOF (2016.08); A23L 33/135 (2016.08); A61 K 38/13 (2013.01) (71) Applicant: Seres Health, Inc., Cambridge, MA (58) Field of Classification Search (US) None See application file for complete search history. (72) Inventors: Matthew R. Henn, Somerville, MA (56) References Cited (US); Geoffrey von Maltzahn, Boston, MA (US); Anthony Mario D'Onofrio, U.S. PATENT DOCUMENTS Northborough, MA (US); Kevin Daniel Litcofsky, Boston, MA (US); David 3,009,864 A 1 1/1961 Gordon-Aldterton et al. 3,228,838 A 1/1966 Rinfret Arthur Berry, Brookline, MA (US); 3,608,030 A 9, 1971 Tint David N. Cook, Brooklyn, NY (US); 4,077,227 A 3, 1978 Larson Noubar B. Afeyan, Lexington, MA 4,205,132 A 5/1980 Sandline (US); John Grant Aunins, Doylestown, 4,655,047 A 4/1987 Temple 4,689,226 A 8, 1987 Nurmi PA (US) 4,839,281 A 6, 1989 Gorbach et al. 5,196.205 A 3/1993 Borody (73) Assignee: Seres Therapeutics, Inc., Cambridge, 5.425,951 A 6/1995 Goodrich MA (US) 5,436,002 A 7/1995 Payne 5,443,826 A 8/1995 Borody (*) Notice: Subject to any disclaimer, the term of this 5,599,795 A 2f1997 McCann 5,648,206 A 7, 1997 Goodrich patent is extended or adjusted under 35 5,951,977 A 9, 1999 Nisbet et al. U.S.C. 154(b) by 0 days. 5,965,128 A 10/1999 Doyle et al. 6,589.771 B1 7/2003 Marshall This patent is Subject to a terminal dis 6,645,530 B1 11/2003 Borody claimer. 7.427,398 B2 9, 2008 Baillon et al. 7.628,982 B2 12/2009 Klaviniskis (21) Appl. No.: 14/592,481 7,632,520 B2 12/2009 Khandelwal 7,708,988 B2 5, 2010 Farmer (22) Filed: Jan. 8, 2015 7,731,976 B2 6, 2010 Cobb 7,763.420 B2 7/2010 Stritzker et al. 7,981,411 B2 7, 2011 Nadeau et al. (65) Prior Publication Data 7.998.473 B2 8/2011 Boileau et al. US 2015/O190435 A1 Jul. 9, 2015 8,021,654 B2 9/2011 Rehberger et al. 8,034,601 B2 10/2011 Boileau (Continued) Related U.S. Application Data FOREIGN PATENT DOCUMENTS (60) Continuation of application No. 14/221,190, filed on Mar. 20, 2014, now Pat. No. 9,028,841, which is a EP 0033584 A3 1, 1981 division of application No. 14/091,201, filed on Nov. EP O433299 A4 4f1992 26, 2013, now Pat. No. 8,906,668, which is a (Continued) continuation of application No. PCT/US2013/071758, filed on Nov. 25, 2013. OTHER PUBLICATIONS Aas, J., Gessert, C.E., and Bakken, J.S. (2003). Recurrent (60) Provisional application No. 61/729,518, filed on Nov. Clostridium difficile colitis: case series involving 18 patients treated 23, 2012, provisional application No. 61/729,519, with donor stool administered via a nasogastric tube. Clinical filed on Nov. 23, 2012, provisional application No. Infectious Diseases 36(5), 580-585. Abrams, R.S., “Open-Label, Uncontrolled Trial of Bowel Steriliza 61/729.520, filed on Nov. 23, 2012, provisional tion and Repopulation with Normal Bowel Flora for Treatment of application No. 61/729,521, filed on Nov. 23, 2012, Inflammatory Bowel Disease.” Current Therapeutic Research, Dec. provisional application No. 61/729.522, filed on Nov. 1997, pp. 1001-1012, vol. 58, No. 12. 23, 2012, provisional application No. 61/729,524, Achtman, M., and Wagner, M. (2008). Microbial diversity and the filed on Nov. 23, 2012, provisional application No. genetic nature of microbial species. Nat. Rev. Microbiol. 6(6), 61/729,515, filed on Nov. 23, 2012, provisional 431-440. application No. 61/729,517, filed on Nov. 23, 2012, (Continued) provisional application No. 61/729.525, filed on Nov. Primary Examiner — Jennifer Graser 23, 2012, provisional application No. 61/729,526, (74) Attorney, Agent, or Firm — Fenwick & West LLP filed on Nov. 23, 2012, provisional application No. 61/729,527, filed on Nov. 23, 2012. (57) ABSTRACT Provided are therapeutic compositions containing Ecobi (51) Int. Cl. oticTM populations for prevention, treatment and reduction A6 IK 38/13 (2006.01) of symptoms associated with a dysbiosis of a mammalian A2.3L 33/35 (2016.01) Subject such as a human. A6 IK 35/74 (2015.01) 11 Claims, 1 Drawing Sheet US 9,533,014 B2 Page 2 (56) References Cited WO WO 2011/03331.0 A1 3, 2011 WO WO 2011/043654 A1 4, 2011 U.S. PATENT DOCUMENTS WO WO 2011/046616 A3 4, 2011 WO WO 2011 (103123 A2 8, 2011 8,039,006 B2 10/2011 Prato WO WO 2011, 107482 A2 9, 2011 8, 147,482 B2 4, 2012 Shimizu WO WO 2011 113801 A1 9, 2011 8, 187,590 B2 5, 2012 Farmer WO WO 2011 107481 A2 9, 2011 8,236,508 B2 8, 2012 Mutharasan WO WO 2011/152566 A2 12, 2011 8,388,996 B2 3/2013 Gehling WO WO 2012/OO9712 A2 1, 2012 8.460,648 B2 6, 2013 Borody WO WO 2012/O16287 A2 2, 2012 8,906,668 B2 12/2014 Henn et al. WO WO 2012/045150 A1 4/2012 9,011,834 B1 4, 2015 McKenzie et al. WO WO 2012/064981 A2 5, 2012 9,028,841 B2 5/2015 Henn et al. WO WO 2012,116289 A2 8, 2012 9,180,147 B2 11/2015 McKenzie et al. WO WO 2012/122478 A1 9, 2012 2001.0036453 A1 11, 2001 Reid WO WO 2012/122522 A2 9, 2012 2004/0028689 A1 2, 2004 Borody WO WO 2012/142605 A1 10, 2012 2004/017O617 A1 9, 2004 Finegold WO WO 2012, 148991 A1 11, 2012 2005, 0180962 A1 8, 2005 Raz WO WO 2012/159023 A2 11/2012 2006, 0046246 A1 3, 2006 Zeng et al. WO WO 2013/O19896 A1 2, 2013 2006,0188523 A1 8, 2006 Pei WO WO 2013,032328 A1 3, 2013 2006/023383.0 A1 10, 2006 Wong WO WO 2013,037O67 A1 3, 2013 2007/014 1139 A1 6, 2007 Vandenberg WO WO 2013,037O68 3, 2013 2009/O197249 A1 8, 2009 Gillevet WO WO 2013,053836 A1 4/2013 2010, OO74872 A1 3, 2010 Blaser et al. WO WO 2013/080561 A1 6, 2013 2010/0215745 A1 8, 2010 LaZZari et al. WO WO 2013, 166031 A1 11, 2013 2011 OO81320 A1 4/2011 Westall et al. WO WO 2013, 171515 A1 11, 2013 2011/O113863 A1 5, 2011 Fuhrmann et al. WO WO 2013, 176774 A1 11, 2013 2011 O189132 A1 8, 2011 Garner et al. WO WO 2014/082050 A1 5, 2014 2011 (028O840 A1 11, 2011 Blaser WO WO 2014, 121298 A2 8, 2014 2012/0020950 A1 1, 2012 Davis et al. WO WO 2014f12 1301 A1 8, 2014 2012, 0021429 A1 1, 2012 Rublee WO WO 2014f12 1302 A2 8, 2014 2012, 0021921 A1 1, 2012 Scott WO WO 2014f12 1304 A1 8, 2014 2012fOO58094 A1 3/2012 Blaser WO WO 2014f145958 A2 9, 2014 2012fOO64592 A1 3/2012 O'Mullan et al. WO WO 2014/153194 A2 9, 2014 2012/O1286.33 A1 5, 2012 Veiga et al. WO WO 2015, O77794 A1 5/2O15 2012/O128634 A1 5, 2012 Veiga WO WO 2015,095241 A2 6, 2015 2012/0148629 A1 6, 2012 Holvoet et al. 2012fO149584 A1 6, 2012 Olle 2012fO1652.15 A1 6, 2012 Andersen OTHER PUBLICATIONS 2012/0177650 A1 T/2012 Borody 2012fO2O7726 A1 8, 2012 Lipkin Accoceberry, I. et al., “One-Step Purification of Enterocytozoon 2012fO238468 A1 9, 2012 Tuk Bieneusi Spores from Human Stools by Immunoaffinity Expanded 2012,0264.637 A1 10, 2012 Brodie 2012fO276.149 A1 11, 2012 Littman Bed Adsorption.” Journal of Clinical Microbiology, May 2001, pp. 2012fO276201 A1 11, 2012 Trachtman 1974-1951, vol. 39, No. 5. 2012,0315249 A1 12, 2012 Olmstead Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G.B., Hota, S., Kim, P., 2013, OO17999 A1 1, 2013 Fremont Lee, C. O'Doherty, K. Vanner, S.J., Weese, J.S., et al. (2012). A 2013/0022575 A1 1, 2013 Cassity Canadian Working Group report on fecal microbial therapy: micro 2013,0045274 A1 2, 2013 Hlavka 2013,0045874 A1 2, 2013 Ehrlich bial ecosystems therapeutics. Can. J. Gastroenterol. 26(7), 457-462. 2013,012 1968 A1 5, 2013 Quay Allen-Vercoe, E., Strauss, J., and Chadee, K. (2011). Fusobacterium 2013, O149339 A1 6, 2013 Honda nucleatum: an emerging gutpathogen? Gut Microbes 2(5), 294-298. 2013/014.9375 A1 6, 2013 Geall Anderson, K.F., Lonsway, D.R., Rasheed, J.K., Biddle, J., Jensen, 2013,0266539 A1 10, 2013 Borody B. McDougal, L.K., Carey, R.B., Thompson, A., Stocker, S., 2014/0045744 A1 2, 2014 Gordon Limbago, B., et al. (2007). Evaluation of Methods to Identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae. J. FOREIGN PATENT DOCUMENTS Clin. Microbiol. 45(8), 2723-2725. Arumugam, M., Raes, J., Pelletier, E. Paslier, D.L., Yamada, T., EP 1107772 B1 4/2006 EP 1631312 B1 9, 2008 Mende, D.R., Fernandes, G.R., Tap, J., Bruls, T., Batto, J.-M., et al. EP 2337569 A2 6, 2011 (2011). Enterotypes of the human gut microbiome. Nature EP 2338989 A1 6, 2011 473(7346), 174-180. EP 2519108 A1 11 2012 Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y.
Load more

Recommended publications
  • Louisiana Morbidity Report
    Louisiana Morbidity Report Office of Public Health - Infectious Disease Epidemiology Section P.O. Box 60630, New Orleans, LA 70160 - Phone: (504) 568-8313 www.dhh.louisiana.gov/LMR Infectious Disease Epidemiology Main Webpage BOBBY JINDAL KATHY KLIEBERT GOVERNOR www.infectiousdisease.dhh.louisiana.gov SECRETARY September - October, 2015 Volume 26, Number 5 Cutaneous Leishmaniasis - An Emerging Imported Infection Louisiana, 2015 Benjamin Munley, MPH; Angie Orellana, MPH; Christine Scott-Waldron, MSPH In the summer of 2015, a total of 3 cases of cutaneous leish- and the species was found to be L. panamensis, one of the 4 main maniasis, all male, were reported to the Department of Health species associated with progression to metastasized mucosal and Hospitals’ (DHH) Louisiana Office of Public Health (OPH). leishmaniasis in some instances. The first 2 cases to be reported were newly acquired, a 17-year- The third case to be reported in the summer of 2015 was from old male and his father, a 49-year-old male. Both had traveled to an Australian resident with an extensive travel history prior to Costa Rica approximately 2 months prior to their initial medical developing the skin lesion, although exact travel history could not consultation, and although they noticed bug bites after the trip, be confirmed. The case presented with a non-healing skin ulcer they did not notice any flies while traveling. It is not known less than 1 cm in diameter on his right leg. The ulcer had been where transmission of the parasite occurred while in Costa Rica, present for 18 months and had not previously been treated.
    [Show full text]
  • Leptospirosis Importance Leptospirosis Is a Bacterial Zoonosis That Is Common Worldwide, Especially in Developing Countries
    Leptospirosis Importance Leptospirosis is a bacterial zoonosis that is common worldwide, especially in developing countries. Organisms are shed in the urine of infected animals, including Weil’s Syndrome, rodents and domesticated animals, which may not show signs of disease. Humans Swamp Fever, Mud Fever, usually become ill after contact with infected urine, or through contact with water, Autumn Fever (Akiyami), soil or food that has been contaminated. Outbreaks have been associated with Swineherd’s Disease, floodwaters. In animals, the clinical signs of leptospirosis are often related to kidney Rice-Field Fever, disease, liver disease or reproductive dysfunction. In humans, many cases are mild or Cane-Cutter’s Fever, asymptomatic, and go unrecognized. In some patients, however, the illness may Hemorrhagic Jaundice, progress to kidney or liver failure, aseptic meningitis, life-threatening pulmonary Stuttgart Disease, hemorrhage and other syndromes. Canicola Fever, Etiology Redwater of Calves Leptospirosis is caused by various species of Leptospira, a spirochete in the family Leptospiraceae, order Spirochaetales. Some Leptospira are harmless saprophytes that reside in the environment, while others are pathogenic. The basic Last Updated: October 2013 unit of Leptospira taxonomy is the serovar. Serovars consist of closely related isolates based on serological reactions to the organism’s lipopolysaccharide. More than 250 pathogenic serovars, and at least 50 nonpathogenic serovars, have been identified. Two different systems are used to classify Leptospira isolates beyond the serovar. Before 1989, all pathogenic isolates belonged to the species L. interrogans and all nonpathogenic organisms were placed in L. biflexa. Leptospira serovars were also grouped, using serological methods, into 24 serogroups. The genus Leptospira has since been reclassified, using genetic techniques, into 21 species.
    [Show full text]
  • Milk, Mucosal Immunity and the Microbiome: Impact on the Neonate Nestlé Nutrition Institute Workshop Series
    Milk, Mucosal Immunity and the Microbiome: Impact on the Neonate Nestlé Nutrition Institute Workshop Series Vol. 94 Milk, Mucosal Immunity and the Microbiome: Impact on the Neonate Editors Pearay L. Ogra Buffalo, NY W. Allan Walker Boston, MA Bo Lönnerdal Davis, CA © 2020 Nestlé Nutrition Institute, Switzerland CH 1814 La Tour-de-Peilz S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com Library of Congress Cataloging-in-Publication Data Names: Nestlé Nutrition Workshop (94th : 2019 : Lausanne, Switzerland), author. | Ogra, Pearay L., editor. | Walker, W. Allan, editor. | Lönnerdal, Bo, 1938- editor. | Nestlé Nutrition Institute, issuing body. Title: Milk, mucosal immunity and the microbiome : impact on the neonate / editors, Pearay L. Ogra, W. Allan Walker, Bo Lönnerdal. Other titles: Nestlé Nutrition Institute workshop series ; v. 94. 1664-2147 Description: Basel ; Hartford : Karger ; Switzerland : Nestlé Nutrition Institute, [2020] | Series: Nestlé Nutrition Institute workshop series, 1664-2147 ; vol. 94 | Includes bibliographical references and index. | Summary: “This publication covers the 94th Nestle Nutritional Institute Workshop, which was designed to provide a comprehensive overview on the latest human milk research and its role in modulating mucosal immunity, the microbiome, and its impact on the neonate. This publication should provide scientific support to anyone seeking a deeper understanding of human milk and its immunological properties, and enlarge the knowledge of those who specialize in human milk research”--
    [Show full text]
  • Vipin Chandra Kalia Editor Quorum Sensing Vs Quorum Quenching: a Battle with No End in Sight Quorum Sensing Vs Quorum Quenching: a Battle with No End in Sight
    Vipin Chandra Kalia Editor Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight Vipin Chandra Kalia Editor Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight 123 Editor Vipin Chandra Kalia Microbial Biotechnology and Genomics CSIR-Institute of Genomics and Integrative Biology Delhi, India ISBN 978-81-322-1981-1 ISBN 978-81-322-1982-8 (eBook) DOI 10.1007/978-81-322-1982-8 Springer New Delhi Heidelberg New York Dordrecht London Library of Congress Control Number: 2014947883 © Springer India 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.
    [Show full text]
  • Who Speaks for the Microbes?
    Special Issue Who Speaks for the Microbes? Stanley Falkow Stanford University School of Medicine, Stanford, California, USA In discussing emerging infectious diseases, slowed and has been replaced by the encroach- the focus is often on the clinical effects of the host- ment of human populations into the domain of parasite relationship, i.e., the impact on the animal species all over the globe. It is little wonder health and survival of humans and animals, that our deliberate destruction of predators and the rather than the examination of the biology of the outgrowth of human populations into virgin land pathogen. It seems fitting to take a moment to with its attendant destruction of habitat led to the reflect on how pathogens “got that way in the first emergence of new diseases such as Lyme disease place.” Thus, while we discuss emerging and murine typhus (spread now by opossums and infections, it is worthwhile to consider that from cat fleas in our slums, instead of by the more classic the beginning of recorded history—in books or rat and rat flea vector—“sic transit gloria mundi”). the pictographs of ancient cultures—infectious diseases have been the leading cause of illness The Enemy Is Us and death. Even today, because of infectious The cartoon character Pogo, invented by Walt diseases most of the world’s population does not Kelly, once announced to his companions that have the luxury of living long enough to succumb “the enemy is us.” I believe that many of what to the chronic diseases of aging. we refer to as emerging diseases are What were and what remain the reasons that characterized better as “diseases of human infectious diseases are still the leading cause of progress.” Thus, many major public health death? I believe there are four answers.
    [Show full text]
  • The Neonatal Window of Opportunity: Setting Rupted, Drives Far-Ranging Clinical Consequences
    e Journal of Immunology VOLUME 198, NUMBER 2 • JANUARY 15, 2017 • WWW.JIMMUNOL.ORG The Macro Influence of the Microbiome am pleased to draw your attention to this, the first ever topical issue of Brief Reviews in The Journal of Immunology. I Through seven Brief Reviews, this issue of The JI high- lights the pervasive impact of the gut microbiome on immune functions, both in the gut and at distal sites, and features a cover chosen from a themed competition for this issue. These compiled Brief Reviews underscore our recent appreci- ation that the far-reaching influence of commensal gut microbes on immune function reflects the coevolution of this symbiotic mi- crobial ecosystem and its mammalian hosts. Authors Torow and Hornef emphasize that the nature of this microbial community in Downloaded from human and mouse early neonates impacts immune homeostasis throughout life (1). Grigg and Sonnenberg explore the reciprocal influence of the identity and localization of the microbiome components on the balance between inflammation and immune homeostasis both within and outside the gut, and point to the therapeutic potential for diseases of chronic inflammation pro- http://www.jimmunol.org/ vided by manipulation of the microbiota-host interactions (2). Elinav and coauthors describe the microbially derived and mi- crobially modified small metabolites whose bioactivity mediates much of the influence on sterile host tissues described in the ac- companying reviews, in part by modulating nutrient content, digestion, inflammation, and epigenetic control of transcription
    [Show full text]
  • A Computational Tool to Identify Unique Drug Targets in Pathogenic Bacteria
    UniDrug-Target: A Computational Tool to Identify Unique Drug Targets in Pathogenic Bacteria Sree Krishna Chanumolu, Chittaranjan Rout, Rajinder S. Chauhan* Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat, Solan, Himachal Pradesh, India Abstract Background: Targeting conserved proteins of bacteria through antibacterial medications has resulted in both the development of resistant strains and changes to human health by destroying beneficial microbes which eventually become breeding grounds for the evolution of resistances. Despite the availability of more than 800 genomes sequences, 430 pathways, 4743 enzymes, 9257 metabolic reactions and protein (three-dimensional) 3D structures in bacteria, no pathogen- specific computational drug target identification tool has been developed. Methods: A web server, UniDrug-Target, which combines bacterial biological information and computational methods to stringently identify pathogen-specific proteins as drug targets, has been designed. Besides predicting pathogen-specific proteins essentiality, chokepoint property, etc., three new algorithms were developed and implemented by using protein sequences, domains, structures, and metabolic reactions for construction of partial metabolic networks (PMNs), determination of conservation in critical residues, and variation analysis of residues forming similar cavities in proteins sequences. First, PMNs are constructed to determine the extent of disturbances in metabolite production by targeting a protein as drug target. Conservation of pathogen-specific protein’s critical residues involved in cavity formation and biological function determined at domain-level with low-matching sequences. Last, variation analysis of residues forming similar cavities in proteins sequences from pathogenic versus non-pathogenic bacteria and humans is performed. Results: The server is capable of predicting drug targets for any sequenced pathogenic bacteria having fasta sequences and annotated information.
    [Show full text]
  • Intestinal Complement Modulates Colitis by Targeting the Gut Microbiota
    Intestinal Complement Modulates Colitis by Targeting the Gut Microbiota The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:39945359 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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
    [Show full text]
  • Infection, Immunology, and Sanitation
    Infection, Immunology, and Sanitation Resource Center for RCCTA CareerTech Advancement https://www.okcareertech.org/educators/resource-center Infection, Immunology, and Sanitation Copyright 2019 Oklahoma Department of Career and Technology Education Resource Center for CareerTech Advancement All rights reserved. Printed in the United States of America by the Oklahoma Department of Career and Technology Education, Stillwater, OK 74074-4364 PHOTO CREDITS: Thinkstock® and Getty Images® Permission granted to download and print this publication for non-commercial use in a classroom or training setting. Infection, Immunology, and Sanitation Objective Sheet SPECIFIC After completing this module, you should be able to: oBJECTIVES 1. Define the term infection. 2. Complete statements that describe the effects of infection on a human host. 3. Complete statements that describe methods used to reduce the spread of infection. 4. Match types of infections and diseases to their descriptions. 5. Describe the phases in the course of a disease. 6. Complete statements that describe the role of the body’s portals of entry and portals of exit in the spread of infectious diseases. 7. List sources of the microorganisms that cause infectious diseases. 8. Select the factors that determine whether a pathogen will cause a disease in a host’s body. 9. Describe the factors that infl uence the virulence of a pathogen in a host’s body. 10. Complete statements concerning the functions of the body’s physical barriers to infection. 11. Match special structures, chemicals, and actions within the body that provide protection against infection to their functions. 12. Define the term immunology. 13. Select true statements concerning types of immunity.
    [Show full text]
  • Indicator Organisms in Meat and Poultry Slaughter Operations: Their Potential Use in Process Control and the Role of Emerging Technologies
    1387 Journal of Food Protection, Vol. 74, No. 8, 2011, Pages 1387–1394 doi:10.4315/0362-028X.JFP-10-433 Review Indicator Organisms in Meat and Poultry Slaughter Operations: Their Potential Use in Process Control and the Role of Emerging Technologies PARMESH K. SAINI,1 HARRY M. MARKS,2 MOSHE S. DREYFUSS,1* PETER EVANS,1 L. VICTOR COOK, JR.,1 AND UDAY DESSAI1 Downloaded from http://meridian.allenpress.com/jfp/article-pdf/74/8/1387/1686427/0362-028x_jfp-10-433.pdf by guest on 02 October 2021 1Microbiology Division, Office Public Health Science, and 2Data Analysis & Integration Group, Office of Data Integration and Food Protection, Food Safety and Inspection Service, U.S. Department of Agriculture, Washington, DC 20250-3700, USA MS 10-433: Received 4 October 2010/Accepted 21 April 2011 ABSTRACT Measuring commonly occurring, nonpathogenic organisms on poultry products may be used for designing statistical process control systems that could result in reductions of pathogen levels. The extent of pathogen level reduction that could be obtained from actions resulting from monitoring these measurements over time depends upon the degree of understanding cause-effect relationships between processing variables, selected output variables, and pathogens. For such measurements to be effective for controlling or improving processing to some capability level within the statistical process control context, sufficiently frequent measurements would be needed to help identify processing deficiencies. Ultimately the correct balance of sampling and resources is determined by those characteristics of deficient processing that are important to identify. We recommend strategies that emphasize flexibility, depending upon sampling objectives. Coupling the measurement of levels of indicator organisms with practical emerging technologies and suitable on-site platforms that decrease the time between sample collections and interpreting results would enhance monitoring process control.
    [Show full text]
  • Hospital Microbiome Variations As Analyzed by High-Throughput Sequencing
    OMICS A Journal of Integrative Biology Volume 23, Number 0, 2019 Research Article ª Mary Ann Liebert, Inc. DOI: 10.1089/omi.2019.0111 Hospital Microbiome Variations As Analyzed by High-Throughput Sequencing Marwa T. ElRakaiby,1,2,* Soha Gamal-Eldin,3,* Magdy A. Amin,1 and Ramy K. Aziz,1,2 Abstract Hospital-acquired infections remain a serious threat to human life and are becoming a top public health issue. As the latest advances in sequencing technologies have allowed the unbiased identification of bacterial com- munities, we aimed to implement emerging omics technologies to characterize a hospital’s microbiome at the center of Cairo, Egypt. To this end, we screened surfaces and inanimate objects in the hospital, focusing on bed sheets and door knobs, with additional screening for resistant microbes and resistance genes. While bacterial load and community composition were not dramatically different between door knobs of hospital units with different hygiene levels, the bacterial communities on door knob samples were richer and more diverse than those detected on bed sheets. Bacteria detected on door knobs were a mix of those associated with dust/ particulate matter/debris (e.g., Bacillus, Geobacillus, Aeribacillus) and skin-associated bacteria (e.g., Staphy- lococcus, Corynebacterium). The latter were among the core genera shared by all analyzed samples. Con- versely, bacteria that were more abundant in bed sheets were not associated with a particular source (e.g., Pseudomonas and Nitrobacter). Resistance screening indicated an expansion of a mobile beta-lactamase- encoding gene (blaTEM), reflecting its current global spread. This study is a first step toward more compre- hensive screening of hospital surfaces and correlating their microbiome with hospital outbreaks or chronic infections.
    [Show full text]
  • The Gut and Pre and Probiotics Candace Becker, APRN, CNS-BC, Rx, CHFH
    4/15/2018 The gut and pre and probiotics Candace Becker, APRN, CNS-BC, Rx, CHFH Objectives: Review the gut pathophysiology and inflammatory process Investigate process of gut inflammation Discuss pre and probiotics and their influence on gut health Evaluate content of common pre and probiotics 1 4/15/2018 Definitions Probiotic – “for life”- nonpathogenic organisms that have no necessary phylogenic (evolutionary) reaction. Considered “good” bacteria that help keep digestive system healthy by controlling growth of harmful bacteria. Prebiotics - carbohydrates that cannot be digested by the human body, but feed probiotics; "a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well being and health." They are dietary fibers with a well- established positive impact on the intestinal microflora. Microflora/microbiome - bacteria and microscopic organisms, especially those living in a particular site or habitat Definitions (cont.) Symbiots – pre and probiotics designed to improve survival of ingested “live microorganisms which, when administered in adequate amounts, confer health benefit on host…” Commensal organisms -- Living in a relationship in which one organism derives food or other benefits from another organism without hurting or helping it. Dysbiosis - microbial imbalance or maladaptation on or inside the body Stress – anything that threatens homeostasis 2 4/15/2018 Some basics… GI tract is home to >500 bacterial species. Bacteria + virome = microbiota Microbiota are responsible for digestion, acquiring nutrients, immune system Bacterial cells outnumber human cells 10:1 Some of the B vitamins, vitamin K, folate and short chain fatty acids are produced by gut bacteria Up to 10% daily energy needs come from gut fermentation Yeast Nutr Metab (London).
    [Show full text]